Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Session 5 has the same title folks...the other sessions including under "Unique Challenges In Emerging Immunotherapies." are still listed when in the live event schedule. The presentation is going to happen.
Tuesday, May 10, 2022
6:00 AM
6:00 AM - 7:40 AM PDT
Session 5: Unique Challenges in Emerging Immunotherapies
LIVE
Session Chair: George Zavoico, PhD, Cue Biopharma
9:00 AM
Welcome Remarks
Barbara Knappmeyer, PhD, The New York Academy of Sciences
Session 5: Unique Challenges in Emerging Immunotherapies
Session Chair: To be announced
9:10 AM
Immune Checkpoint Blockade in Glioblastoma
David Reardon, MD, Dana Farber Cancer Institute
9:40 AM
How Do CAR T Cells Kill Cancer?
Marcela V. Maus, MD, PhD, Massachusetts General Hospital, Harvard Medical School
10:10 AM
Immunotherapeutic Approaches to Glioblastoma Treatment
Vinay K. Puduvalli, MD, MD Anderson Cancer Center
Virtual session
Join session
8:10 AM
8:10 AM - 9:10 AM PDT
Session 6: Unique Challenges in Emerging Immunotherapies (Continued)
11:10 AM
Autologous Tumor Lysate-loaded Dendritic Cell Vaccination for Glioblastoma
Paul Mulholland, MBBS, MSc, PhD, FRCP, University College Hospital *
11:40 AM
Independent Drug Action in Immunotherapy: Implications for Drug Discovery and Precision Medicine
Peter Sorger, PhD, Harvard Medical School
Virtual session
Included session
9:10 AM
9:10 AM - 9:40 AM PDT
Session 7: Short Talks
12:10 PM
Targeting SIRPa as a Therapeutic Strategy For the Treatment of Breast Cancer Brain Metastasis
Jessica Mackert, PhD, Wake Forest School of Medicine
12:25 PM
Notch Orchestrates A Multifaceted Immune Evasion Program in Hepatocellular Carcinoma
Katherine Linblad, Icahn School of Medicine at Mount Sinai
Virtual session
Included session
11:10 AM
11:10 AM - 12:55 PM PDT
Session 8: Keynote & Session 9: Cytokines as Therapeutics
Session 8: Keynote
Session Chair: George Zavoico, PhD, CueBiopharma
2:10 PM
Cancer and the Immune System
Abul K. Abbas, MBBS, University of California San Francisco School of Medicine
Session 9: Cytokines as Therapeutics
Session Chair: George Zavoico, PhD, CueBiopharma
2:55 PM
Cell Type-Selective Targeting Improves Anti-Tumor Activity and Safety of Cytokines
Ivana Djuretic, PhD, Asher Biotherapeutics
3:25 PM
Expansion of Tumoral CD8 T Cells with a Targeted IL-15 Mutein
Robert C. Rickert, PhD, Pfizer
Featured session
Virtual session
Included session
12:55 PM
12:55 PM - 1:55 PM PDT
Session 10: Poster Session
3:55 PM
Poster Session
4:55 PM
Day 2 - Closing Remarks
Barbara Knappmeyer, PhD, The New York Academy of Sciences
Featured session
Included session
At NYAS when paying for one session you get the hold day at NYAS. Go to session list before going into session 5 it lists the entire sessions under the same title “Unique Challenges…”
Margaret
If you have questions about sharing information here is the email address that I contacted originally about sharing Dr. Liau’s presentation:
events@nyas.org
Take care,
Margaret
Email from NYAS I just got this morning:
NYAS embargo policy
Hi Margaret,
Your inquiry was forwarded to me. Our standard policy is that unpublished data cannot be reported unless a direct check with the speaker is made. Are you a journalist?
--Roger Torda
NYAS Communications
So if you share, be sure you have the correct permissions lined up from the required parties.
Take care all!
Margaret
The title of Unique Challenges In Emerging Immunotherapies is from 9:00 am until 12:40 pm EST see below’s agenda for the sessions on May 10th. So it appears the title is determined by NYAS not the company or Dr. Liau.
Margaret
Agenda
Admission Item
May 10 Virtual Only Registration
$120.00
Sessions
Session 5: Unique Challenges in Emerging Immunotherapies
5/10/22, 9:00 AM - 5/10/22, 10:40 AM
$0.00
Session 6: Unique Challenges in Emerging Immunotherapies (Continued)
5/10/22, 11:10 AM - 5/10/22, 12:10 PM
$0.00
Session 7: Short Talks
5/10/22, 12:10 PM - 5/10/22, 12:40 PM
$0.00
Session 8: Keynote & Session 9: Cytokines as Therapeutics
5/10/22, 2:10 PM - 5/10/22, 3:55 PM
$0.00
Session 10: Poster Session
5/10/22, 3:55 PM - 5/10/22, 4:55 PM
$0.00
I don’t think it’s Musk either. However, I checked and the interview with Elon is 10:00-10:15 PST technically outside of when Dr. Liau’s presentation is. I personally don’t truly care…just thought of it as an interesting aside.
Margaret
Just more digging on a Saturday night. Musk is co-founder of Neuralink which is a neurotechnology company that develops implantable brain machine interfaces. I haven’t done any further investigation into his company but it sounds like him attending is 1% more plausible than before I found this.
https://en.m.wikipedia.org/wiki/Neuralink
That’s what I think too, I’m not sure if NYAS cares what name people use to identify themselves as. The results will be exciting imo regardless of who is in attendance.
I’m fairly certain this was a joke. You enter what name you go by it isn’t tied to the registration information.
I just checked the list of attendees and I cannot guarantee the identity of the person on the attendee hub but Elon Musk is scheduled to attend the conference.
I’m curious given the following NWBO PR what you believe Dr. Liau will be discussing on Tuesday?
May 4, 2022: Presentation About Phase 3 Trial of DCVax-L for Glioblastoma To Be Made At New York Academy of Sciences
Margaret
https://nwbio.com/presentation-about-phase-3-trial-of-dcvax-l-for-glioblastoma-to-be-made-at-new-york-academy-of-sciences/
A thought…how do you get big pharma off of your back as a small biotech company? If BP’s huge revenue streams are threatened by NWBO, as a way to survive in such a cutthroat industry, show all of them what partnering with NWBO will look like. A platform that potentially enhances each of their income streams. Get the big pharmas to compete to partner with you, not bury you.
All of this is just my hopeful speculation and musings. I think it’s a brilliant plan on how to navigate, survive and thrive in this industry.
GLTA
Yes. Here is part of an article discussing shorting stocks:
If the stock goes down after the sale of the 1,000 shares at $50—say to $45—then $5,000 is moved from the broker's account to the short seller's account, which can be removed by the short seller. His margin requirement goes down by 50% of the $5,000. On the other hand, if the stock goes up to $55, then $5,000 is moved from the short seller's margin account to the broker's account and the short seller's minimum maintenance requirement will increase.
These money transfers take place exactly the same way whether you do a regular short sale or a naked short sale. There are similar future transfers if you have sold calls or sold single stock futures. When you buy puts and fully pay for them, there are none of these money transfers after the purchase, although the value of your account certainly fluctuates as the value of the puts fluctuates.
https://www.investopedia.com/articles/optioninvestor/09/naked-short-selling.asp
My understanding is the only time they are not required to pay is if they can bankrupt a company.
Margaret
Or a joint venture with NWBO? Why poor money into a vaccine development when they could partner with NWBO on a vaccine closer to regulatory approval. Just my idle thoughts this fine rainy Saturday morning.
Margaret
From your confirmation email copy your confirmation code then click on the view or modify your registration link. Paste your confirmation number in and it will direct you to your confirmation page. Halfway down the page right above the registration summary is the link to the attendee hub. I hope this helps!
No, I believe they are all the attendees of the 3 day conference. I stated in my post that this may or may not be all inclusive as I do not know what everyone attending the conference is there to see. Likewise I do not know if it’s a requirement to be registered as an attendee so there could be many more attending that didn’t fill out the attendee hub profile.
Margaret
Here is an email I just sent the events coordinator at the conference:
Good Afternoon,
I am attending Dr. Liau’s presentation on Tuesday virtually. I wanted to know what is allowed to share and what is not from the presentation. As this is a paid event I do not want to share anything that would compromise the conference getting paid. That being said there are a lot of investors in NWBO who will not be able to attend and are requesting as much information as is possible to share. I wanted to ask directly what is okay to share from my attending the conference virtually and what is not.
Thank you for your time,
Here is the current list of attendees to Dr. Liau's presentation at NYAS on Tuesday (this list may or may not be all inclusive):
***JUST SAW THE OTHER POSTS WITH MORE DETAILS***
Adam Kesselman Adrianne Wong Albert Marshall Alessandra Rigamonti Alia Minhas Alireza Shahmoradi Alton Boynton Amanda Krasco Amelia Zellander Amy Shank Andrew Kolodziej Andrew Kozbial Ania Andrzejczyk Antonio Ferraro Arthur Kunz Aryana Javaheri Bala S Benedikt Bosbach Benjamin Reichstein Bob Murphy Brad Silver Brandy Chavez Branko Krstevski Brian Egolf Brian Wells Bryan Clay Canhua Xiao Carol Powers Carol Schembri Carolyn Cho Catherine Kelley Charles Wilson Christina Yu Christopher Ward Claudia Tapia Cofer Black Corinne Hill Craig Atwood Cristina Paraschivescu Daniel Moore Daniel Weinstock Daniela Salvemini Daqing Wang David Gutzman David Margol David Schwed David Shields David Soto-Pantoja David Zarling David J Houston Di Feng Dillon Phan Doreen Robotnick Dori Thomas-Karyat Douglas Burtrum Douglas Duckworth Dr. Fahar Merchant Elizabeth Gorodetsky Elizabeth Stirling Eric Hine Erica Ma Erik Ramos Erik Sternberg Federica Mornata Fred Valentine Gary Bennett Georgi Lukov Gilbert Lee Gitte Pedersen Glenn Seale Gloria Dawodu Gregory Zivic Guixan Jin Gustavo Teran Hala Abuzied Harry Aine Himan Sharma Hsuan-Chen Liu Ila Joshi Injin Bang Irina Matei Jacob Kushkuley Jacquelynn Golubov James Passin Jean Davis Jennifer O'Neil Jenny Zilberberg Jeppe Lind Andreasen Jerome Schentag Jerry Jasinowski Jessica Mackert Jesus Gomez-Navarro Jie Huang Joan E Lappin Jody Symons Joe Pratt Joel Gordon John Carlyle John Johannes John Panther John Troisi John Will Jon Zibell Jorge Postigo Ferrnandez Jozef Bossowski Justin Brockway Justin Keister Juuso Juismanen Kai Blau Kalina Abrol Kamilah Ryan Kanika Jain Kasia Karwacz Katherine Cook Katherine Kaiser Katherine Lindblad Keerthi Nawarathna Kenneth LaMontagne Kenysha Clear Kim Arndt Kristen Belcourt Kristin Bernick Kristyn D Power Laura Carter Lawson Day Lekhana Bhandary Liang Liu Linda Powers Lola Yu Lorenzo Maso Lucas Young Lynn Biderman Madison Doolittle Maja Milanovic Margaret Monson Marjorie Sexton Mark Cooper Mark Wesalowski Marnix Bosch Martin White Mary Laughlin Masakatsu Suzuki Matt Kelly Matthew Hoberman Mehdi Eshraghi Melanie Thomas Melissa Gantt Michael Bigger Michael Lee Michael Zimmerman Michelle Bradbury Mike Arnold Mike Scott Mitchel Villereal Nathalie Fiaschi Navid Malik Navpreet Tung Nicholas Collette Nikos Kourtis Nzinga Mack Olivier Libouban Pamela Garzone Patrick Sciortino Paul Bullock Peter Davis Peter Heiberger Peter Kelley Piril Erler Priyanka Ram Qiaozhi Wei Rajeswara Rao Randall Hough Rebecca Kulok Robert Decraene Robert Klawonn Robert Rollins Robert Shinn Robert Wild Roberta Hayes Rodney Lantos Roger Parent Roger Phillips Ron Feiner Ruben Fernandez-Rodriguez Rusian Novosiadly Saida Dadi-Mehmetaj Samar Elorbany Samyukta Mallick Sara Cuadrado Castano Saul Tawil Scott Zamore Sebastiano Cremonini Sergey Kozhenkov Sergio Trombetta Shannon Ferry Shaoxian Sun Sharon Shepherd Shashi Murthy Silvia Alvarez Stephen Hoffmann Stephen Laderman Steve Derby Steve Klawonn Steven Barnhill Steven Brem Steven Horklulak Takamitsu Hattori Talia Nguyen Tawny Chandler Terell Orum-Moore Tim Dick Toshihiko Torigoe Vanessa Arce Vinh Nguyen Wade Kovash Wei Hu Welby Montalvo-Ortiz Wen Lin Wen Hong Lin Wenqian He William Taggart Woo Joo Xin Zhao Yifen Lu Yonina Bykov Yu (Christie) Zhang Yufeng Wei
Cannot wait to hear Dr. Liau's presentation on Tuesday! May the regulators get this approved for the patients who so desperately need better treatment options than the current SOC.
GLTA,
Margaret
I just registered for the conference. I can’t wait to see Dr. Liau’s presentation!!!!!
Wimike - Here is part of the SEC rules on public disclosure. The rules do not mention that the initial announcement has to be free. It does handle requirements of a company doing simultaneous disclosure in the case of selective groups receiving information not publicly disclosed. With who is running NWBO, I’m certain they are aware of these rules.
“for an intentional selective disclosure, the issuer must make public disclosure simultaneously; for a non-intentional disclosure, the issuer must make public disclosure promptly.”
https://www.sec.gov/rules/final/33-7881.htm
Margaret
Dr. Liau’s lecture at 13:38 was discussing development of future trial designs and treatment decisions by their cancer markers. My understanding is these types of immunotherapy trials didn’t differentiate between mgmt methylated and unmethylated gbm. My impression was she was talking about historical immunotherapy trials that included a now known population that doesn’t respond well to immunotherapy. For me she was implying the 20-25% result was due to this population’s inclusion in the trial and obscuring the statistical significance of the trial for the group that responds well to immunotherapy.
I promise I only hit the button once...maybe I thought I was buying more NWBO stock? I've asked to have the extra posts removed and I'm posting from another computer. Sorry for the duplicate posts all.
Margaret
GLTA
DCS,
Prayers for you.
I agree with your 10 mil.
Good Luck Everyone!
The conference is being held in Philadelphia which is in the EST.
Dr. Luau’s lecture at 13:38 was discussing development of future trial designs and treatment decisions by their cancer markers. My understanding is these types of immunotherapy trials didn’t differentiate between mgmt methylated and unmethylated gbm. My impression was she was talking about historical immunotherapy trials that included a now known population that doesn’t respond well to immunotherapy. For me she was implying the 20-25% result was due to this population’s inclusion in the trial and obscuring the statistical significance of the trial for the group that responds well to immunotherapy.
Regarding ASCO, in booking the theater, does anyone know the cancellation policy for the theater? I am guessing the revenue loss from a cancellation of the theater is vastly different than pulling an abstract or cancelling a scheduled conference talk.
I want to thank all the long time investors here that day in and day out refute the false narratives that are recurring on this BB. Everyday, every hour, 24/7. Thank you!!!
vator - I agree. Various articles from established news sources within biomedical sciences and the business sector is encouraging to me. We’ve seen an uptick in activity and whether I’m following breadcrumbs or eating them, they are getting fatter and closer together.
Margaret
DCVax article yesterday in Microcap Daily. I apologize if this is already posted.
Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) Major Move Northbound as Sawston Facility is Licensed by (HTA) and (MHRA) & Biotech Awaits Imminent Phase III Top Line Data
https://microcapdaily.com/northwest-biotherapeutics-inc-otcmkts-nwbo-sawston-facility-is-licensed-by-hta-and-mhra-biotech-awaits-phase-iii-top-line-data/
Article regarding DCVax results updated 2/19/2022. It was originally written May 18, 2018. I am still searching for what was actually updated from the original article.
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6/metrics
Wimike-I agree! Hopefully the Business Weekly UK article that came out after market close today will positively effect the SP tomorrow. Below is the link that was posted earlier on this BB. GLT patients and longs.
Margaret
https://www.businessweekly.co.uk/news/biomedtech/cancer-vaccine-production-starts-cambridge
Gary,
There are no words that can take away your loss. Prayers for healing for you and your family.
Margaret
TDD, Excellent work! This helped me understand some of the reasons for the company’s quiet period decision. GLTU, all patients and longs.
Thanks TDD for all you do! Keep up the good fight! Well done NWBO. GLTU
There were updates today from the MHRA’s Innovative Licensing and Access Pathway. Nothing specifically identifying NWBO. However, it does show the MHRA is actively working on the build out of their new pathway supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access.
https://www.gov.uk/guidance/innovative-licensing-and-access-pathway
Thanks Sojo for continuing to share your NWBO charts. It’s reassuring to have someone with your long time analysis of NWBO’s specific stock price trends. Happy New Year to you and yours. May 2022 be your best year ever! GLTA
Margaret
I agree with your assessment of this BB. There are a lot of professionals here that have many years of experience in various industries that add such value to explaining NWBO's complex business operations. I wish there was a BB that didn't include the Fudsters. Posters providing differing opinions as value to any discussion board. The conflict I see here is a lack of respect of others opinions. I miss the face to face social norms of agreeing to disagree that gets lost in the ethernet. I found this BB after 3 days of the Yahoo BB. Thank God that I did or I would have sold based on all of the negativity and fear that is spewed on that particular BB. Thankfully my decision to invest and make a commitment to the success of NWBO happened before I saw a single post on any BB. Thanks all of you for your exceptional DD (you know who you are) and good luck to all in 2022.
Margaret
I don’t know how the “fellas” on this BB predict future value of a stock. My numbers are not based solely on the mathematics that others apply to their calculations. My time as a long is going into it’s second year and I’ve not seen a price change based on the math of this stock. I have however seen a variety of price changes based on emotions. I believe there is a LOT more value in NWBO’s patents and future indications of efficacy in other cancers. What is that worth? Maybe not at the beginning of 2023 but my numbers as given are a guesstimate of a future value based on many things occurring in the next year. Good luck to you in 2022. Margaret
I’ll put in my guesstimate. $28 without Flaskworks in the mix in 2022. If Flaskwork’s approved for manufacturing in 2022 (overly optimistic? I am very much that!) then $52. Happy New Year and may many unexpected joys be yours in the New Year.